Absci Stock Jumps

AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips
The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other industries.
Absci Stock Jumps As AMD Invests $20M To Boost AI Drug Discovery
AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the company entered into a strategic collaboration with Advanced Micro Devices Inc (NASDAQ:AMD) to enhance its AI drug discovery capabilities.
AMD invests $20M in AI-powered drug discovery company Absci
Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop new hardware and software optimized for the healthcare sector. The effort will place particular emphasis on developing technologies that can advance drug discovery.
Advanced Micro Devices (AMD) Invests in Absci for AI-Driven Drug Discovery with High-Performance Computing Solutions
We recently published a list of 13 AI News and Ratings You Probably Missed. In this article, we are going to take a look at where Advanced Micro Devices, Inc. (NASDAQ:AMD) stands against other AI stocks.
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads,
AMD is going head-to-head with Nvidia in AI-backed drug discovery with new deal
Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.
AMD Invests in Absci to Strengthen AI Chip Presence in Drug Discovery
In a strategic move to expand its footprint in the healthcare sector, Advanced Micro Devices (AMD) has announced a $20 million investment in Absci, a Washington-based drug-discovery company. This investment not only highlights AMD’s ambition to diversify its market presence but also emphasizes the growing role of artificial intelligence (AI) in revolutionizing life sciences.
Absci Announces Strategic Collaboration With AMD To Advance AI-Driven Drug Discovery
Absci Corporation (ABSI), a Washington-based biotechnology company, Wednesday has announced a strategic collaboration with AMD to
AMD to invest $20m in Absci to boost AI drug discovery tech
AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design models.
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class ...
GEN20h
StockWatch: Will Expanding to Life Sciences Reverse AMD’s Stock Decline?
Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that followed a six-month decline in the stock price.
Absci Shares Rise 27% on Report of $20 Mln Investment from Advanced Micro Devices
Shares of Absci on Wednesday jumped following a report on a $20 million investment from Advanced Micro Devices. The stock was up 27% to $3.89 in pre-market trading. Through Tuesday's close, shares ...